Supramolecular Assembly of Human Pulmonary Surfactant Protein SP-D.
Pulmonary surfactant protein D (SP-D) is a glycoprotein from the collectin family that is a component of the lung surfactant system. It exhibits host defense and immune regulatory functions in addition to contributing to the homeostasis of the surfactant pool within the alveolar airspaces. It is known that the SP-D monomer forms trimers, which further …
Airway Therapeutics Announces Appointment of Chief Medical Officer
(Cincinnati, OH—August 24, 2018) Airway Therapeutics, LLC (“Airway”), a biotechnology company focused on developing new interventions for acute and chronic lung diseases, announces the appointment of Paul Kingma, MD, PhD to the position of Chief Medical Officer (“CMO”) as of August 1, 2018 in preparation for clinical development of AT-100, a recombinant form of human …
Airway Therapeutics Closes $11M Series B Round of Financing
(Cincinnati, OH– April 17, 2018) Airway Therapeutics, a biotechnology company focused on developing new interventions for acute and chronic lung diseases has secured $11 million in Series B financing from new and existing investors. The financing comes as Airway Therapeutics steadily meets milestones in the development of its lead product AT-100, a recombinant form of …
Airway Therapeutics, LLC Obtains License on Glycotope Cell Line
Core Manufacturing Technology is Key Milestone on Airway’s Path to Market Cincinnati, Ohio, 11 September 2017- Airway Therapeutics, LLC, [Airway] a biotech company focused on developing new interventions for acute and chronic lung diseases, today announced an exclusive licensing agreement with the German biotechnology company, Glycotope GmbH [Glycotope]. Under the terms of this agreement, Airway …
Airway Therapeutics Closes $6.3M in Finance Round
Financing furthers Company’s efforts to improve outcomes for very premature infants Cincinnati OH—March 6, 2017 Airway Therapeutics, a biotechnology company focused on developing new interventions for acute and chronic lung diseases, beginning with premature infants, has secured $6.3 million in bridge financing from new and existing investors. Cincinnati Children’s Hospital Medical Center, CincyTech and Queen …
Airways Therapeutics Featured on Bio International
New Protein Replacement Therapy Makes Breathing Easier for Babies Hospitals are getting better at helping pre-term babies survive, but that help is having an unintended consequence. Each year over 160,000 pre-term babies in the US and Europe alone are at risk for developing bronchopulmonary dysplasia – or BPD. Of these pre-term babies, 49 percent will …
Airway Therapeutics Featured on TechOhio
Airway Therapeutics Helping Preemies’ Lungs Develop Written by Robert Leitch. When a baby is born prematurely, they often need mechanical ventilation and oxygenation — two medical tools that help keep preemies alive. However, these tools can also lead to inflammation and infection in the lung, which can result in bronchopulmonary dysplasia (BPD). BPD is a lung …
Airway Therapeutics in the Media
The following link provides a summary of Airway Therapeutics coverage in the news media.
Airway Therapeutics Raises $4.6 Million in Series A Funding
Financing Follows FDA Orphan Designation for Startup Working to Improve Outcomes for Very Premature Infants (Cincinnati OH— September 10, 2014) Airway Therapeutics, a biotechnology company working to prevent a debilitating lung condition in extremely premature infants, has secured $4.6 million in Series A financing. CincyTech led the round, with participation from Cincinnati Children’s Hospital Medical …
